Novartis’ Zykadia smashes Phase III target for lung cancer

pharmafile | September 23, 2016 | News story | Medical Communications, Research and Development Novartis, lung cancer, zykadia 

Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating its efficacy in treating patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer.

Zykadia, an orally-administered selective inhibitor of anaplastic lymphoma kinase, showed a significant improvement in progression-free survival in previously untreated patients compared to standard chemotherapy.

Alessandro Riva, global head of Oncology Development and Medical Affairs at Novartis Oncology, explained: “Zykadia has proven to be an important treatment option for ALK+ NSCLC patients who have progressed following treatment with crizotinib. We are pleased to see these topline results show promise in untreated patients with advanced disease, and look forward to sharing these data with regulatory authorities in the coming months.”

Zykadia has been approved in 55 countries and generated $24 million in Q2 sales.

Matt Fellows

Related Content

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …


AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard

Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the …

Novartis announce digital collaboration with HPE

Swiss pharma company, Novartis, has announced a collaboration with Hewlett Packard Enterprise (HPE), to accelerate …

Latest content